RBC Capital initiated coverage of Apogee Therapeutics (APGE) with an Outperform rating and $60 price target The firm is optimistic on the company’s potential to deliver clinically differentiated biologics. Apogee’s early clinical and more recent Phase II atopic dermatitis data demonstrated APG777 and its combo therapies’ advantageous properties, the analyst tells investors in a research note. RBC sees large revenue opportunities across several immunology and inflammation indications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Wall Street Sees Massive Growth Potential in These 3 Russell 2000 Stocks
- 3 Best Stocks to Buy Now, 8/28/2025, According to Top Analysts
- Apogee Therapeutics price target raised to $87 from $78 at BofA
- Promising Prospects for Apogee Therapeutics: Buy Rating Backed by Strong Trial Results and Financial Health
- Apogee Therapeutics Faces Supply Chain Risks Amid Geopolitical Tensions and Regulatory Challenges